Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome - Wikidata - wikimedia - TriplyDB

Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome

Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome

http://www.wikidata.org/entity/Q34176798

about

Novel Therapies for Eosinophilic Disorders Anti-IL5 therapy for asthma and beyond Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs Novel targeted therapies for eosinophil-associated diseases and allergy Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder.Eosinophils: changing perspectives in health and disease.Biologic therapies targeting eosinophils: current status and future prospects.Therapeutic approaches to patients with hypereosinophilic syndromes.Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.Novel targeted therapies for eosinophilic disorders ICON: Eosinophil Disorders Eosinophils affect functions of in vitro-activated human CD3-CD4+ T cells.Mepolizumab.Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.Marked and persistent eosinophilia in the absence of clinical manifestations.Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders.Mepolizumab: First Global Approval.Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?Hypereosinophilia in Children and Adults: A Retrospective Comparison.Successful treatment of steroid resistant hypereosinophilic syndrome with low-dose CsA The identification of eosinophilic gastroenteritis in prednisone-dependent eosinophilic bronchitis and asthma.Biologic Agents for the Treatment of Hypereosinophilic Syndromes.Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.The Eosinophil: for better or worse, in sickness and in health.Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.Guideline for the investigation and management of eosinophilia.

P2860

Q26799600-54AB4288-9722-4243-8737-07C9F064893E Q26866943-B907DE53-5A00-44DC-82A8-104415D81E34 Q27003331-5413D321-59DB-4445-827A-11BEE4032134 Q28067081-D3480359-59C8-4B26-BB3B-14E3F4C703C6 Q34444620-E692609C-C5D5-46DF-A95D-B62244791598 Q34544937-D085E07A-D86E-45E7-8A85-ED648160F916 Q35146265-D4D0E0E2-E550-4986-AFA9-A0A19D3C513C Q35170969-95744167-46A4-4276-B763-D58AE26C779A Q35565533-50CA831E-5B41-421E-9D1A-F26CC6B99E7F Q35857340-BC300C54-92D3-4A3C-B271-1858F29AAE3F Q36573038-67A349BB-A110-49E4-AAF8-DA4C96D001DF Q36763565-01ACD8DE-41CE-446C-A7DE-E654E390508C Q36834826-F08F7211-B9EA-4069-8848-A8FC4215ED16 Q36859237-2DEF5D58-8F63-47B4-84C8-5064624046F1 Q36977252-E845AB30-9344-4D96-9F2E-2AEA20AF9A15 Q37059851-F38B7947-A947-47DC-A8F0-87D62BA9E26F Q37605322-52E9E518-B6FF-4CE3-9D5E-B5C0ED5F8F9F Q37957225-A56E159C-8A40-4091-B97F-FFF7A27FFBD9 Q38394577-A9171538-9CC4-4A12-AD5E-AC265CBD43F5 Q38646902-D33019DA-CA5E-4B15-A60C-F8A89E50F955 Q39201543-E0F18A16-C766-4D42-B397-897750C7BE96 Q40693176-7298B9E0-3AE8-4D7C-8420-EFFE97DFE484 Q41876524-1B74B9BB-2BDD-41D3-8117-9FFB01E83390 Q42700871-B06FCC0E-BF77-4C95-9E74-006BF43C1DB7 Q47848286-10F37D63-0991-467C-A1D7-343B74D905BD Q52571066-33614673-192C-475F-98E0-967C6820DEA6 Q52729256-A10A0513-906D-46DD-BD1D-FB937A968529 Q54114931-363C5B90-4AB9-44E8-96EB-02492F6DEEEB Q55059996-F1B4637E-85E9-4878-A0F2-04ACE37795AD

P2860

Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome

http://www.wikidata.org/entity/Q34176798

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Mepolizumab as a corticosteroi ...... ant hypereosinophilic syndrome

@ast

Mepolizumab as a corticosteroi ...... ant hypereosinophilic syndrome

@en

Mepolizumab as a corticosteroi ...... ant hypereosinophilic syndrome

@nl

type

label

Mepolizumab as a corticosteroi ...... ant hypereosinophilic syndrome

@ast

Mepolizumab as a corticosteroi ...... ant hypereosinophilic syndrome

@en

Mepolizumab as a corticosteroi ...... ant hypereosinophilic syndrome

@nl

prefLabel

Mepolizumab as a corticosteroi ...... ant hypereosinophilic syndrome

@ast

Mepolizumab as a corticosteroi ...... ant hypereosinophilic syndrome

@en

Mepolizumab as a corticosteroi ...... ant hypereosinophilic syndrome

@nl

P1433

Q34176798-176DDA24-5006-4FBA-A854-2D2F4D6A9807

P1476

Q34176798-50553998-8DE5-46E8-B791-61C4E23F48FB

P2093

Q34176798-1112AA1B-8F0D-40C7-A68A-816494491B59

Q34176798-1ABF0678-20EC-4A72-A5F2-4522B345F8E2

Q34176798-3D73E129-D70D-42BC-A689-061A92DB0002

Q34176798-45FE05BC-A63F-453C-853D-F6F6CD253351

Q34176798-51841793-3E5B-4C87-AB5A-7B1977F50FD4

Q34176798-57E0D020-231C-476C-BD85-CCC471988700

Q34176798-7EB529E5-A386-459D-A21E-560E8A9E6CE9

Q34176798-EE6925C2-5100-40C4-ABFE-8674171DB53D

Q34176798-F8214D34-BC04-4ED1-B820-AB9C39A1DD61

P2860

Q34176798-0EBD3938-85DA-4F5B-98CB-949EC9DDFF07

Q34176798-1437ECE4-7439-4DAF-9DCE-C0F2D59206B0

Q34176798-5748AE69-5962-4BD0-912F-F68B47A1C1FD

Q34176798-5CABD467-CC40-4BB5-8EF5-73C9D6FAE5D3

Q34176798-5E1BA086-38CF-4AEE-9A12-48B43537FC4A

Q34176798-67A9C559-265D-470D-852D-F04CCA761F27

Q34176798-6D12D6BA-3E23-45B9-B125-44C4CEB876CD

Q34176798-72ECC6AA-8768-44C9-8EDC-3C7D773FF66E

Q34176798-75DFDB8B-DCA4-4AFE-914D-701DF493FDE9

Q34176798-8B4557BB-A670-4B35-BD5A-FC4ED4CB5EC3

P304

Q34176798-64C6060F-8AE3-424C-87B1-A408731F2D27

P31

Q34176798-94A5E0E5-F5A2-46DF-AAE1-B0A400AEC2A4

P356

Q34176798-653CE4A1-461A-4441-AFA8-4933ED009DF1

P407

Q34176798-EEF1498B-1851-4201-B8D9-1DCABE8CF30B

P433

Q34176798-E08F14B1-ABCB-4782-B750-EDF47C283182

P478

Q34176798-B4B03CE5-1EA5-484D-9276-BC8E36DBBB4B

P50

Q34176798-713C52A7-FFDC-48A0-B5BE-98D059716253

Q34176798-E774847E-0BD3-457D-B1DE-1572DFCA8BF7

P577

Q34176798-273C5EE4-14F9-46B7-B1FF-AACC79C57938

P5875

Q34176798-6B882439-CD6A-47EC-B0B3-534E99D9F973

P698

Q34176798-738BA9C9-3B63-44A1-BADF-C24A27711743

P921

Q34176798-351D67D7-D8C3-4FF9-B07F-0993A8E6058B

Q34176798-5ACC8BB1-5AAB-4134-84CB-1EEAEFEA6064

P932

Q34176798-2A7B01AF-892B-4BD5-9565-F4A9834A50D6

P356

J.JACI.2010.06.049

P1433

The Journal of Allergy and Clinical Immunology

P1476

Mepolizumab as a corticosteroi ...... ant hypereosinophilic syndrome

@en

P2093

Ann Georgelas

http://www.w3.org/2001/XMLSchema#string

Aurore de Lavareille

http://www.w3.org/2001/XMLSchema#string

Florence Roufosse

http://www.w3.org/2001/XMLSchema#string

Gerald J Gleich

http://www.w3.org/2001/XMLSchema#string

Liliane Schandené

http://www.w3.org/2001/XMLSchema#string

Liqiang Xi

http://www.w3.org/2001/XMLSchema#string

Lori Wagner

http://www.w3.org/2001/XMLSchema#string

Mark Raffeld

http://www.w3.org/2001/XMLSchema#string

Michel Goldman

http://www.w3.org/2001/XMLSchema#string

P2860

Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity.

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy

The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.

Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome.

Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia.

Lymphocytic variant hypereosinophilic syndromes.

T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome.

Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells.

Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.

P304

828-835.e3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACI.2010.06.049

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46109873

http://www.w3.org/2001/XMLSchema#string

P698

20810155

http://www.w3.org/2001/XMLSchema#string

P921

P932

2950246

http://www.w3.org/2001/XMLSchema#string